Harvard Bioscience out of compliance with Nasdaq audit committee rule after board resignation

HARVARD BIOSCIENCE INC

Notified Nasdaq on June 18, 2025 of non-compliance with Listing Rule 5605(c)(2)(A) due to Alan Edrick's resignation.
Audit Committee now has only two members; one vacancy from Edrick's departure effective June 10, 2025.
Cure period runs until earlier of next annual meeting or June 10, 2026; company plans to appoint independent director.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.